Advertisement

Waltham biotech ImmunoGen Inc., which announced today a deal with Novartis worth potentially $250 million, also reported positive clinical data in relation to trastuzumb-DM1, its treatment of breast cancer.

The treatment indicated a 47.8 percent response rate in patients taking T-DM1, compared to a 41.4 percent response rate in patients treated with Herceptin and chemotherapy. T-DM1 also had half the number of serious side effects as the standard Herceptin and chemotherapy treatment, according to ImmunoGen officials.

SOURCE

Advertisement
Advertisement